Research is drawing attention to a detail that becomes strategically interesting for CBD providers like hashhash.ch: terpenes – those aromatic compounds that give cannabis its characteristic smell – not only activate CB1 receptors but also modulate the effects of cannabinoids such as CBD and THC. Project CBD recently summarized studies showing that terpenes and cannabinoids together create a more complex profile than isolated active compounds. Beta-caryophyllene (BCP) is at the center of attention: the terpene is one of the most common in the cannabis plant and is also found in black pepper, basil, oregano, and cinnamon. The FDA has already approved BCP as a flavoring and fragrance substance in food.
For the market, this represents a shift away from pure CBD isolates toward full-spectrum or broad-spectrum products that preserve the natural terpene profile. Swiss manufacturers and online retailers could differentiate products through targeted terpene profiles – for example, with elevated BCP content for specific use scenarios. Growing technical literature on beta-caryophyllene and potential applications such as chronic conditions or liver health also creates new marketing and product positioning angles, without making medical claims. Understanding these plant mechanisms becomes a competitive advantage in a maturing market.
Further analysis can be found at Project CBD.
